Skip to main content
SpringerLink
Log in

Pleuropericarditis related to the use of mesalamine

  • Case Report
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Schroder H, Campbell DES: Absorption, metabolism, and excretion of salicylazosulphapyridine in man. Clin Pharmacol Ther 13:539–551, 1972

    Google Scholar 

  2. Das KM, Dubin R: Clinical Pharmacokinetics of sulphasalazine. Clin Pharmacokinet 1:406–425, 1976

    Google Scholar 

  3. Agnholt J, Soerensen HT, Rasmussen SN, et al: Cardiac hypersensitivity to 5-aminosalicylic acid. Lancet 2:1135, 1989

    Google Scholar 

  4. Patwardhan RV, Heilpern J, Brewster AD, Darra JJ: Pleuropericarditis: An extraintestinal complication of inflammatory bowel disease. Arch Intern Med 143:94–96, 1983

    Google Scholar 

  5. Barr-Locke D: Sulfasuxidine-induced lupus syndrome in a patient with Crohn's disease. Am J Gastroenterol 77:614–615, 1982

    Google Scholar 

  6. Clementz GL, Dolin BJ: Sulfasalazine-induced lupus erythematosis. Am J Med 84:535–538, 1988

    Google Scholar 

  7. Deboever G, Devogelaere R, Holvoet G: Sulfasalazine-induced lupus-like syndrome with cardiac tamponade in a patient with ulcerative colitis. Am J Gastroenterol 84:85–86, 1989

    Google Scholar 

  8. FDA rare adverse reaction with Rowasa. FDA Drug Bull 19:17–18, 1989

    Google Scholar 

  9. Kristensen KS, Hoegholm A, Bohr L, et al: Fatal myocarditis associated with mesalazine. Lancet 335:605, 1990

    Google Scholar 

  10. Jenss H, Becker EW, Weber P: Pericardial effusion during treatment with 5-aminosalicylic acid in a patient with Crohn's disease. Am J Gastroenterol 85:332–333, 1990

    Google Scholar 

  11. Sandberg-Gertzen H, Jarnerot G, Tysk C: Long-term treatment with olsalazine of ulcerative colitis: Safety and relapse prevention: A follow-up study. Scand J Gastroenterol 23:48–50, 1988

    Google Scholar 

  12. Miner P, Hanauer S, Robinson M, et al: Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Dig Dis Sci 40:296–304, 1995

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. From the Division of Gastroenterology and Division of Cardiology, Albert Einstein Medical Center, Philadelphia, Pennsylvania

    Navjyot Gujral MD,  Frank Friedenberg MD, Jill Friedenberg MS, George Gabriel DO, Morris Kotler MD & Gary Levine MD

Authors
  1. Navjyot Gujral MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Frank Friedenberg MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jill Friedenberg MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. George Gabriel DO
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Morris Kotler MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gary Levine MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gujral, N., Friedenberg, F., Friedenberg, J. et al. Pleuropericarditis related to the use of mesalamine. Digest Dis Sci 41, 624–626 (1996). https://doi.org/10.1007/BF02282352

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02282352

Key words

Search

Navigation